Avadel Pharmaceuticals Stock (NASDAQ:AVDL)
Previous Close
$7.91
52W Range
$6.38 - $19.09
50D Avg
$8.05
200D Avg
$11.71
Market Cap
$787.53M
Avg Vol (3M)
$1.24M
Beta
1.52
Div Yield
-
AVDL Company Profile
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
AVDL Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ALKS | Alkermes plc |
| ITCI | Intra-Cellular Therapies, Inc. |
| IRWD | Ironwood Pharmaceuticals, Inc. |
| DERM | Journey Medical Corporation |
| ASRT | Assertio Holdings, Inc. |
| LFCR | Lifecore Biomedical, Inc. |
| DVAX | Dynavax Technologies Corporation |
| NBIX | Neurocrine Biosciences, Inc. |
| EVOK | Evoke Pharma, Inc. |
| ANIP | ANI Pharmaceuticals, Inc. |
| AQST | Aquestive Therapeutics, Inc. |
| AMRX | Amneal Pharmaceuticals, Inc. |